Press releases

Reinforcing company's ongoing commitment to leadership in the global medical technology market.

REPRISE II data honored as Best Abstract 2013 at PCR London valves course

Represents significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System.

Unlike medications alone, bronchial thermoplasty provides benefits that last for years rather than hours

Boston Scientific will participate in the healthcare conference on September 11 in Boston. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on September 9 in New York. Learn how to watch the webcast or replay.

First implantations in Zhejiang province and Beijing mark the launch of the COGNIS CRT-D in the Chinese market.

Products join the company's growing portfolio of next generation EP tools designed to redefine ablation technology.

Innovative bare metal stent designed to treat Peripheral Artery Disease.

Public offering consists of $600 million of 2.650% notes due October 1, 2018 and $450 million of 4.125% notes due October 1, 2023.

Company expects to receive the net offering proceeds upon closing on August 13, 2013, subject to customary closing conditions.

"As we continue to expand our portfolio, our team is inspired to deliver meaningful innovation to more patients globally," said president and CEO Mike Mahoney.

System is next-generation 3D mapping and navigation solution for use in cardiac catheter ablations and other electrophysiology (EP) procedures.

Next generation intravascular ultrasound catheter improves image quality and deliverability

First patient treated in OPTIMISE clinical trial evaluating safety, efficacy of occipital nerve stimulation using Precision™ system.

Device facilitates delivery of interventional devices in complex PCI procedures.

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2013. Learn how to tune in.

Transaction to accelerate Boston Scientific expansion in growing electrophysiology market

Cardiac pacing device also features technology to help identify patients with severe sleep apnea.

New family of pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient’s overall heart failure status.

Outcomes follow recent NICE guidance supporting safety and effectiveness of subcutaneous implantable defibrillators.

VANTAGE study interim data presented at International Congress of Parkinson's Disease and Movement Disorders in Sydney.

Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. ...

Company continues to demonstrate its commitment to women's health with a research and education grant of more than $1 million for the SUPeR clinical trial.

GUIDE DBS is the world's first Deep Brain Stimulation visual simulation system.

Boston Scientific will participate in the healthcare conference on May 30 in Boston. Learn how to watch the webcast or replay.

Interim data from REDUCE-HTN clinical program presented today at EuroPCR

New data presented in late-breaking clinical trial session at EuroPCR demonstrated successful deployment of the Lotus™ Valve in the first 60 patients with minimal paravalvular regurgitation at 30 days.

Positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease.

Bronchial Thermoplasty shown to provide long term asthma control over a five-year period after treatment.

More than 24 clinical presentations will feature new data and analyses on Boston Scientific endoscopy products.

Company to present a diversified set of data at the annual EuroPCR Scientific Program May 21-24 in Paris.

Study evaluates clinical outcomes of self-expanding metal stents as a bridge to surgery.

Industry-leading battery life reduces the frequency of replacement surgery.

Company offers mapping system with IntellaMap Orion™ mapping catheter in effort to significantly enhance physician treatment options.

Clinical trial data demonstrated significant reductions in both cardiovascular and all death compared to warfarin.

Boston Scientific will participate in the healthcare conference on May 15 in Las Vegas. Learn how to watch the webcast or replay.

New line of ablation catheters for treating type 1 atrial flutter is designed to provide physicians with high resolution, precise, multidimensional information.

Forty-two clinical presentations will provide new insights about Boston Scientific research in cardiovascular disease, including atrial fibrillation and sudden cardiac arrest.

"We continue to be encouraged but not satisfied with our operating performance," said CEO Mike Mahoney.

Earth Week celebration focuses on 3,900-panel project at the company’s international distribution center in Quincy.

Innovative device quickly anchors leads and catheters.

SAMURAI study designed to confirm the safety and effectiveness of ImageReady™ MR Conditional pacing system in the magnetic resonance imaging (MRI) environment.

World's first and only system with Illumina 3D™ software and 32 contacts is designed to provide pain relief to a broad spectrum of chronic pain patients.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2013. Learn how to tune in.

Results Revealed at CIT 2013

Deadly but preventable cancer is a focus during colorectal cancer awareness month

Separate study demonstrates PROMUS Element stent has significantly less vessel straightening than the Xience V® stent.

WATCHMAN® device continues to demonstrate positive clinical outcomes for patients with atrial fibrillation.

Preliminary data in PREVAIL clinical trial met two out of three co-primary endpoints.

First presentation of the preliminary results of all three co-primary endpoints to be revealed during American College of Cardiology 2013 Annual Scientific Sessions.

New tool available to assist in the treatment of peripheral arterial disease.

Clinical presentations will provide new insights on Boston Scientific research in cardiovascular disease, including aortic valve disease and atrial fibrillation.

Boston Scientific will participate in the healthcare conference on February 26 in New York. Learn how to watch the webcast or replay.

Extensive sales resources, distribution network and service capabilities are expected to enable Boston Scientific to reach substantially more accounts, customers and patients in Japan.

Boston Scientific will participate in the healthcare conference on February 25 in New York. Learn how to watch the webcast or replay.

The next advance in durable polymer stent technology from Boston Scientific is now available in Europe and other select geographies.

Boston Scientific will participate in the healthcare conference on February 13 in New York. Learn how to watch the webcast or replay.

Organizations team up to raise awareness and make a call to action for European governments to develop comprehensive chronic pain treatment programs.

“I am confident we are taking the critical steps that are needed to return our company to long-term growth,” said president and CEO Mike Mahoney.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 and FY ended December 31. Learn how to tune in.

International, multi-center study focuses on patients with paroxysmal atrial fibrillation.

Learn how to tune in or watch the Investor Day replay.

A live webcast and replay will be available. Learn how to tune in.

Company begins evaluation of its next generation pacing leads.

Close the Gap initiative urges fans to learn their risk factors for heart disease.

World's first and only system with 32 contacts and 32 dedicated power sources is designed to provide pain relief to a broad spectrum of chronic pain patients.

Study to compare clinical outcomes of self-expanding metal stents (SEMS) versus plastic stents for the treatment of biliary strictures caused by chronic pancreatitis.

Stent system study to support FDA and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions; received CE approval last month.

Devices projected to have up to twice the longevity of comparable products.

Company to consolidate Natick, Mass. headquarters into existing Marlborough site to create collaborative campus setting; to be completed by summer 2014.

MADIT-RIT clinical trial study results published today in the New England Journal of Medicine

Appointment completes company's CEO transition plan; Mahoney Replaces Interim CEO William H. (Hank) Kucheman.

Innovative bioabsorbable coating is the first to complete absorption shortly after drug elution ends at three months.

Language update supports the strong safety profile for PROMUS Element and PROMUS Element Plus Stents.

PLATINUM Long Lesion clinical results presented at TCT 2012 show no heart attack or stent thrombosis at two-year follow-up.

Twelve-month data presented at TCT 2012 support safety and efficacy of Epic stent in iliac stenting.

Results presented on cost effectiveness and clinical benefits for older patients of the WATCHMAN® Left Atrial Appendage Closure Device; Lotus™ Aortic Valve System feasibility trial results reviewed.

Clinical presentations will provide new insights on Boston Scientific research in coronary and peripheral artery disease, including aortic valve disease and atrial fibrillation.

"We remain focused on executing our strategy to drive this organization back to revenue growth,” said CEO Hank Kucheman.

REPRISE II study results expected to support CE Mark and other regulatory filings.

Victory™ guidewires are designed to facilitate crossing of resistant lesions.

Pending addition of next generation mapping and navigation system would expand company portfolio into complex electrophysiology procedures.

Learn how to tune in for the webcast or the replay.

Disorders affect nearly 30 million American women; new research shows high prevalence of patients not understanding their treatment options.

S-ICD System is the world's first and only commercially available completely subcutaneous implantable defibrillator.

S-ICD System is world's first and only commercially available completely subcutaneous implantable defibrillator.

First and only commercially available DBS system to incorporate multiple independent current control, which is designed to selectively stimulate targeted areas in the brain.

Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions

RELIANCE® 4-FRONT™ lead designed to streamline surgical procedure for treatment of heart failure and sudden cardiac arrest.

Company to acquire innovative, minimally invasive technologies for the treatment of coronary chronic total occlusions.

New bronchial thermoplasty procedure codes effective January 1, 2013.

Boston Scientific will participate in the healthcare conference on September 12. Learn how to watch the webcast or replay.

System is the world's first rechargeable SCS device; approval provides physicians with an additional diagnostic option for patients with chronic intractable pain.

World's first rechargeable SCS device approved for peripheral nerve stimulation for patients with chronic intractable pain of the trunk.

Newly revised European Society of Cardiology guidelines include LAA closure devices.

PARIS (July 27, 2012) -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its INGENIO™ and ADVANTIO™ pacemakers in patients in need of a magnetic resonance...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.828 billion and adjusted earnings per share of $0.17 for the second quarter ended June...

Boston Scientific Corporation (NYSE: BSX) has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and...

Boston Scientific Corporation (NYSE: BSX) will webcast its second-quarter 2012 financial results conference call on Thursday, July 26, at 8:00 a.m....